National Toxicology Program (NTP); NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM); Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM): Ten-Year Anniversary Symposium and Five-Year Plan, 72727-72729 [E7-24799]
Download as PDF
<![CDATA[
mstockstill on PROD1PC66 with NOTICES
Federal Register / Vol. 72, No. 245 / Friday, December 21, 2007 / Notices
Reporters: Depository institutions,
Edge and agreement corporations, U.S.
branches and agencies of foreign banks
Annual reporting hours: 1,623 hours
Estimated average hours per response:
1.0 hour
Number of respondents: 1,623
General description of report: This
information collection is mandatory (12
U.S.C. 248(i), 248–1, and 464). The
information submitted by respondents
for the payments system risk reduction
program may be accorded confidential
treatment under the Freedom of
Information Act (FOIA) (5 U.S.C. § 552
(b)(4)). In addition, information reported
in connection with the second and third
resolutions may be protected under
Section (b)(8) of FOIA, to the extent that
such information is based on the
institution’s CAMELS rating, and thus is
related to examination reports prepared
by, on behalf of, or for the use of an
agency responsible for the regulation or
supervision of financial institutions (5
U.S.C. § 552(b)(8)).
Abstract: Federal Reserve Banks
collect these data annually to provide
information that is essential for their
administration of the Federal Reserve’s
Payments System Risk (PSR) policy. The
reporting panel includes all financially
healthy depository institutions with
access to the discount window. The
Report of Net Debit Cap comprises three
resolutions, which are filed by a
depository institution’s board of
directors depending on its needs. The
first resolution is used to establish a de
minimis net debit cap and the second
resolution is used to establish a selfassessed net debit cap. The third
resolution is used to establish
simultaneously a self-assessed net debit
cap and maximum daylight overdraft
capacity. Copies of the model
resolutions are located in Appendix B,
of the PSR policy, that can be found at
https://www.federalreserve.gov/
paymentsystems/psr/relpol.htm.
Current actions: In an effort to
streamline the resolutions filed by
institutions eligible for maximum
daylight overdraft capacity, two former
resolutions were combined into one:
resolution 3a, collateralized capacity,
and resolution 3b, in-transit securities.
These resolutions were replaced by the
maximum daylight overdraft capacity
resolution that combines the board of
directors’ approval of the institution’s
self-assessment as well as its maximum
daylight overdraft capacity level.
VerDate Aug<31>2005
18:37 Dec 20, 2007
Jkt 214001
72727
Board of Governors of the Federal Reserve
System, December 17, 2007.
Jennifer J. Johnson,
Secretary of the Board.
[FR Doc. E7–24785 Filed 12–20–07; 8:45 am]
Board of Governors of the Federal Reserve
System, December 18, 2007.
Jennifer J. Johnson,
Secretary of the Board.
[FR Doc.E7–24832 Filed 12–20–07; 8:45 am]
BILLING CODE 6210–01–S
BILLING CODE 6210–01–S
FEDERAL RESERVE SYSTEM
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR Part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The application also will be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Additional information on all bank
holding companies may be obtained
from the National Information Center
website at www.ffiec.gov/nic/.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than January 18,
2008.
A. Federal Reserve Bank of Kansas
City (Todd Offenbacker, Assistant Vice
President) 925 Grand Avenue, Kansas
City, Missouri 64198–0001:
1. Ambage, Inc., Las Vegas, Nevada; to
become a bank holding company by
acquiring 100 percent of the voting
shares of First Financial Services, Inc.,
and thereby acquire First National Bank
and Trust Company, both in Falls City,
Nebraska.
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
National Toxicology Program (NTP);
NTP Interagency Center for the
Evaluation of Alternative Toxicological
Methods (NICEATM); Interagency
Coordinating Committee on the
Validation of Alternative Methods
(ICCVAM): Ten-Year Anniversary
Symposium and Five-Year Plan
National Institute of
Environmental Health Sciences
(NIEHS), National Institutes of Health
(NIH), HHS.
ACTION: Announcement of public
symposium and availability of
document.
AGENCY:
SUMMARY: NICEATM invites attendance
at a public symposium to mark the tenth
anniversary of ICCVAM. The
symposium, entitled ‘‘Celebrating Ten
Years of Advancing Public Health and
Animal Welfare With Sound Science:
Envisioning New Directions in
Toxicology’’ will be held February 5,
2008, at the U.S. Consumer Product
Safety Commission (CPSC)
Headquarters in Bethesda, MD. The
NICEATM–ICCVAM Five-Year Plan
(2008–2012) will also be discussed and
made available on February 5.
DATES: The symposium will be held on
February 5, 2008. Those interested in
attending the symposium are
encouraged to register with NICEATM
by February 1, 2008, although
registration will also be available onsite.
ADDRESSES: The symposium will be
held in the CPSC Hearing Room, located
at CPSC Headquarters, Bethesda Towers
Bldg., 4330 East West Highway,
Bethesda, MD. Registration information
and other details about the symposium
can be found on the NICEATM-ICCVAM
Web site at https://iccvam.niehs.nih.gov/
meetings/10thAnnivSymp/
10thAnnivSymp.htm or by contacting
NICEATM (see FOR FURTHER
INFORMATION CONTACT below). The
NICEATM–ICCVAM Five-Year Plan will
be available at the symposium and
electronically on the NICEATM–
ICCVAM Web site at https://
iccvam.niehs.nih.gov/docs/
5yearplan.htm after February 5. Print
copies may be obtained by contacting
NICEATM.
E:\FR\FM\21DEN1.SGM
21DEN1
72728
Federal Register / Vol. 72, No. 245 / Friday, December 21, 2007 / Notices
Ms.
Debbie McCarley, NICEATM, NIEHS,
P.O. Box 12233, MD EC–17, Research
Triangle Park, NC 27709, (telephone)
919–541–2384, (fax) 919–541–0947, (email) niceatm@niehs.nih.gov.
SUPPLEMENTARY INFORMATION:
mstockstill on PROD1PC66 with NOTICES
FOR FURTHER INFORMATION CONTACT:
Background
The Director of the NIEHS established
an ad hoc ICCVAM in September 1994
to respond to requirements in the NIH
Revitalization Act of 1993 (42 U.S.C.
285l-1, Public Law 103–43). This Act
required NIEHS to establish criteria for
the validation and regulatory acceptance
of alternative toxicological testing
methods. NIEHS was also required to
recommend a process to achieve the
regulatory acceptance of scientifically
valid alternative test methods. The ad
hoc ICCVAM was comprised of
representatives from 15 Federal
agencies, which are now represented on
ICCVAM.
In 1997, the ad hoc ICCVAM
published its final report, Validation
and Regulatory Acceptance of
Toxicological Test Methods. In the same
year, NIEHS established a standing
ICCVAM committee to implement a
process by which new test methods of
interagency interest could be evaluated
and to coordinate cross-agency issues on
development, validation, acceptance,
and national and international
harmonization of toxicological test
methods. The ICCVAM Authorization
Act of 2000 (42 U.S.C. 285l-3, Public
Law 106–545) established ICCVAM as a
permanent interagency committee of
NIEHS under NICEATM. The law was
enacted ‘‘To establish, wherever
feasible, guidelines, recommendations,
and regulations that promote the
regulatory acceptance of new or revised
scientifically valid toxicological tests
that protect human and animal health
and the environment while reducing,
refining, or replacing animal tests and
ensuring human safety and product
effectiveness.’’
Over the last 10 years, ICCVAM, with
scientific support from NICEATM, has
evaluated over 185 test methods with
the potential to reduce, refine or replace
the use of animals in regulatory safety
testing. ICCVAM has developed and
transmitted recommendations to Federal
agencies for alternative methods for the
four most commonly used toxicity tests.
These science-based technical
evaluations have been used to support
adoption of test methods as guidelines
by the Organisation for Economic Cooperation and Development and other
international organizations. NICEATM
and ICCVAM have also worked with
Federal agencies and other stakeholders
VerDate Aug<31>2005
18:37 Dec 20, 2007
Jkt 214001
to link research and development
activities to the standardization and
validation of alternative test methods
that may be used in regulatory testing.
The symposium on February 5, 2008,
will recognize the 10-year anniversary
of ICCVAM and discuss future
directions in toxicology testing and the
NICEATM–ICCVAM Five-Year Plan.
Preliminary Agenda
• Welcome
• ICCVAM and NICEATM: The First
Ten Years
• A Vision Towards the Future: The
NICEATM–ICCVAM Five-Year Plan
• The Evolution and Future of
Toxicology: Where We’ve Come From
and Future Prospects
• Toxicology Testing in the 21st
Century: A Vision and a Strategy—A
Report of the National Research
Council of the National Academies
• Future Directions in Test Method
Development—Toxicology Research,
Development, Translation, and
Validation: Insights and Activities
from selected ICCVAM Agencies:
NIEHS/NTP, EPA, FDA
• Panel Discussion—Toxicology
Research, Development, Translation,
and Validation: The Way Forward for
ICCVAM and Its Stakeholders
• Closing Remarks
Symposium Attendance and
Registration
The symposium will be held on
Tuesday, February 5, 2008, from 1–5
p.m., in the CPSC Hearing Room,
located at CPSC Headquarters, Bethesda
Towers Bldg., 4330 East West Highway,
Bethesda, MD. The symposium is open
to the public and there is no charge to
attend; attendance is limited only by the
available space. Individuals who plan to
attend are encouraged to register in
advance with NICEATM. Registration
information is available on the
NICEATM–ICCVAM Web site at https://
iccvam.niehs.nih.gov/meetings/
10thAnnivSymp/10thAnnivSymp.htm
or by contacting NICEATM (see FOR
FURTHER INFORMATION CONTACT above).
Persons needing special assistance in
order to attend, such as sign language
interpretation or other reasonable
accommodation, should contact 919–
541–2475 voice, 919–541–4644 TTY
(text telephone, through the Federal
TTY Relay System at 800–877–8339), or
e-mail to niehsoeeo@niehs.nih.gov.
Requests should be made at least seven
days in advance of the event.
NICEATM–ICCVAM Five-Year Plan
NICEATM and ICCVAM, working in
conjunction with Federal agency
program offices, have prepared the
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
NICEATM–ICCVAM Five-Year Plan.
The plan describes how NICEATM and
ICCVAM will facilitate the research,
development, translation (activities
carried out to characterize if there is
evidence of relevance and applicability
of a test method for a specific testing
purpose), validation, and regulatory
acceptance of alternative test methods.
Acceptance of such methods will
reduce, refine, and replace the use of
animals in testing, while maintaining
scientific quality and the protection of
human health, animal health, and the
environment. Development of the plan
took place over a 14-month period
during which there were multiple
opportunities for comment on the plan
by ICCVAM stakeholders, the public,
and the Scientific Advisory Committee
on Alternative Toxicological Methods
(see Federal Register notices: Vol. 71,
No. 218, pp. 66172–73, November 13,
2006; Vol. 72, No. 83, pp. 23831–32,
May 1, 2007; and Vol. 72, No. 83, pp.
23832–33, May 1, 2007).
The plan addresses ICCVAM’s vision
to play a leading role in fostering and
promoting the development, validation,
and regulatory acceptance of
scientifically sound alternative test
methods both within the Federal
government and internationally.
Implementing this plan involves four
key challenges. The first challenge is to
identify priority areas for the next five
years and to conduct and facilitate
activities in those areas. The second
challenge involves identifying and
promoting research initiatives that are
expected to support the future
development of innovative alternative
test methods. The third challenge is to
foster the acceptance and appropriate
use of alternative test methods through
outreach and communication. The last
challenge is to develop partnerships and
strengthen interactions with ICCVAM
stakeholders in order to facilitate
meaningful progress.
The NICEATM–ICCVAM Five-Year
Plan will be presented at the February
symposium and copies will be available.
The NICEATM–ICCVAM Five-Year Plan
will also be available electronically after
February 5 on the NICEATM–ICCVAM
Web site at https://iccvam.niehs.nih.gov/
docs/5yearplan.htm. Print copies may
be obtained by contacting NICEATM
(see FOR FURTHER INFORMATION CONTACT
above).
Background Information on ICCVAM
and NICEATM
ICCVAM is an interagency committee
composed of representatives from 15
Federal regulatory and research agencies
that use or generate toxicological
information. ICCVAM conducts
E:\FR\FM\21DEN1.SGM
21DEN1
Federal Register / Vol. 72, No. 245 / Friday, December 21, 2007 / Notices
technical evaluations of new, revised,
and alternative methods with regulatory
applicability and promotes the scientific
validation and regulatory acceptance of
toxicological test methods that more
accurately assess the safety and hazards
of chemicals and products and that
refine, reduce, or replace animal use.
The ICCVAM Authorization Act of 2000
(available at https://
iccvam.niehs.nih.gov/docs/about_docs/
PL106545.pdf) establishes ICCVAM as a
permanent interagency committee of the
NIEHS under NICEATM. NICEATM
administers ICCVAM and provides
scientific and operational support for
ICCVAM-related activities. NICEATM
and ICCVAM work collaboratively to
evaluate new and improved test
methods applicable to the needs of
Federal agencies. Additional
information about ICCVAM and
NICEATM is available on the
NICEATM–ICCVAM Web site at https://
iccvam.niehs.nih.gov.
Dated: December 12, 2007.
Samuel H. Wilson,
Acting Director, National Institute of
Environmental Health Sciences and National
Toxicology Program.
[FR Doc. E7–24799 Filed 12–20–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
Privacy Act of 1974; Report of a New
System of Records
Centers for Medicare &
Medicaid Services (CMS), Department
of Health and Human Services (HHS).
ACTION: Notice of a New System of
Records (SOR).
mstockstill on PROD1PC66 with NOTICES
AGENCY:
SUMMARY: In accordance with the
requirements of the Privacy Act of 1974,
we are proposing to establish a new
system titled, ‘‘Money Follows the
Person (MFP) Demonstration (MFPD),
System No. 09–70–0593.’’ The
demonstration, created by section 6071
of the Deficit Reduction Act of 2005
(Pub. L. 109–171), provides to states a
total of $1.75 billion in competitive
grants. MFP demonstration grants have
been awarded to 30 states and the
District of Columbia. The states and the
District of Columbia are using the grant
funding to transition Medicaid
beneficiaries who need long-term care
services from institutional-based care to
community-based care. The purpose of
the demonstration is to help states
continue their efforts to restructure their
VerDate Aug<31>2005
18:37 Dec 20, 2007
Jkt 214001
long-term care systems and shift the
historical emphasis from institutional
care to community-based care. The
demonstration is based on the premise
that many Medicaid beneficiaries
currently residing in institutions want
to live in the community and could do
so if they had the adequate support, and
that it would cost less than Medicaid
currently spends to care for institutional
care.
The purpose of this system is to
collect and maintain individually
identifiable information on Medicaid
recipients, those who participate in the
MFP demonstration and other
comparable Medicaid recipients, and to
collect and maintain program level
information on grantee implementation
of the MFP demonstration. Information
retrieved from this system may be
disclosed to: (1) Support regulatory,
reimbursement, and policy functions
performed within the agency or by a
contractor, grantee, or consultant; (2)
assist another Federal or state agency
with information to contribute to the
accuracy of CMS’s proper payment of
Medicaid benefits, enable such agency
to administer a Federal health benefits
program, or to enable such agency to
fulfill a requirement of Federal statute
or regulation that implements a health
benefits program funded in whole or in
part with Federal funds; (3) support an
individual or organization for a research
project or in support of an evaluation
project related to the prevention of
disease or disability, the restoration or
maintenance of health, or payment
related projects; (4) support litigation
involving the agency; and (5) combat
fraud, waste, and abuse in certain
Federally-funded health benefits
programs. We have provided
background information about the new
system in the ‘‘Supplementary
Information’’ section below. Although
the Privacy Act requires only that CMS
provide an opportunity for interested
persons to comment on the proposed
routine uses, CMS invites comments on
all portions of this notice. See ‘‘Effective
Dates’’ section for comment period.
DATES: Effective Date: CMS filed a new
SOR report with the Chair of the House
Committee on Government Reform and
Oversight, the Chair of the Senate
Committee on Homeland Security &
Governmental Affairs, and the
Administrator, Office of Information
and Regulatory Affairs, Office of
Management and Budget (OMB) on
December 14, 2007. To ensure that all
parties have adequate time in which to
comment, the new system will become
effective 30 days from the publication of
the notice, or 40 days from the date it
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
72729
was submitted to OMB and the
Congress, whichever is later. We may
defer implementation of this system or
one or more of the routine use
statements listed below if we receive
comments that persuade us to defer
implementation.
The public should address
comments to the CMS Privacy Officer,
Division of Privacy Compliance,
Enterprise Architecture and Strategy
Group, Mail-stop N2–04–27, 7500
Security Boulevard, Baltimore,
Maryland 21244–1850. Comments
received will be available for review at
this location by appointment during
regular business hours, Monday through
Friday from 9 a.m.–3 p.m., eastern time.
FOR FURTHER INFORMATION CONTACT: Effie
Shockley, Division of Advocacy and
Special Initiatives, Disabled and Elderly
Health Programs Group, Center for
Medicaid and State Operations, Mail
Stop S2–14–26, Centers for Medicare &
Medicaid Services, 7500 Security
Boulevard, Baltimore, MD 21244–1849.
She can be reached by telephone at 410–
786–8639, or via e-mail at
Effie.Shockley@cms.hhs.gov.
ADDRESSES:
The
demonstration, created by section 6071
of the Deficit Reduction Act of 2005
(Pub. L. 109–171), provides states a total
of $1.75 billion in competitive grants to
transition Medicaid beneficiaries who
need long-term care services from
institutional-based care to communitybased care and to use enhanced
matching funds to continue their work
to restructure their long-term care
systems. The purpose of the
demonstration is to help states continue
their efforts to restructure their longterm care systems and shift the
historical emphasis from institutional
care to community-based care. The
demonstration is based on the premise
that many Medicaid beneficiaries
currently residing in institutions want
to live in the community and could do
so if they had adequate support, and it
would cost less than Medicaid currently
spends to care for institutional care.
SUPPLEMENTARY INFORMATION:
I. Description of the Proposed System of
Records
A. Statutory and Regulatory Basis for
SOR
The statutory authority for this system
is given under Section 6071 of the
Deficit Reduction Act of 2005.
B. Collection and Maintenance of Data
in the System
This system will collect and maintain
individually identifiable and other data
collected on Medicaid recipients and
E:\FR\FM\21DEN1.SGM
21DEN1
]]>Agencies
[Federal Register Volume 72, Number 245 (Friday, December 21, 2007)]
[Notices]
[Pages 72727-72729]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-24799]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Toxicology Program (NTP); NTP Interagency Center for the
Evaluation of Alternative Toxicological Methods (NICEATM); Interagency
Coordinating Committee on the Validation of Alternative Methods
(ICCVAM): Ten-Year Anniversary Symposium and Five-Year Plan
AGENCY: National Institute of Environmental Health Sciences (NIEHS),
National Institutes of Health (NIH), HHS.
ACTION: Announcement of public symposium and availability of document.
-----------------------------------------------------------------------
SUMMARY: NICEATM invites attendance at a public symposium to mark the
tenth anniversary of ICCVAM. The symposium, entitled ``Celebrating Ten
Years of Advancing Public Health and Animal Welfare With Sound Science:
Envisioning New Directions in Toxicology'' will be held February 5,
2008, at the U.S. Consumer Product Safety Commission (CPSC)
Headquarters in Bethesda, MD. The NICEATM-ICCVAM Five-Year Plan (2008-
2012) will also be discussed and made available on February 5.
DATES: The symposium will be held on February 5, 2008. Those interested
in attending the symposium are encouraged to register with NICEATM by
February 1, 2008, although registration will also be available on-site.
ADDRESSES: The symposium will be held in the CPSC Hearing Room, located
at CPSC Headquarters, Bethesda Towers Bldg., 4330 East West Highway,
Bethesda, MD. Registration information and other details about the
symposium can be found on the NICEATM-ICCVAM Web site at https://
iccvam.niehs.nih.gov/meetings/10thAnnivSymp/10thAnnivSymp.htm or by
contacting NICEATM (see FOR FURTHER INFORMATION CONTACT below). The
NICEATM-ICCVAM Five-Year Plan will be available at the symposium and
electronically on the NICEATM-ICCVAM Web site at https://
iccvam.niehs.nih.gov/docs/5yearplan.htm after February 5. Print copies
may be obtained by contacting NICEATM.
[[Page 72728]]
FOR FURTHER INFORMATION CONTACT: Ms. Debbie McCarley, NICEATM, NIEHS,
P.O. Box 12233, MD EC-17, Research Triangle Park, NC 27709, (telephone)
919-541-2384, (fax) 919-541-0947, (e-mail) niceatm@niehs.nih.gov.
SUPPLEMENTARY INFORMATION:
Background
The Director of the NIEHS established an ad hoc ICCVAM in September
1994 to respond to requirements in the NIH Revitalization Act of 1993
(42 U.S.C. 285l-1, Public Law 103-43). This Act required NIEHS to
establish criteria for the validation and regulatory acceptance of
alternative toxicological testing methods. NIEHS was also required to
recommend a process to achieve the regulatory acceptance of
scientifically valid alternative test methods. The ad hoc ICCVAM was
comprised of representatives from 15 Federal agencies, which are now
represented on ICCVAM.
In 1997, the ad hoc ICCVAM published its final report, Validation
and Regulatory Acceptance of Toxicological Test Methods. In the same
year, NIEHS established a standing ICCVAM committee to implement a
process by which new test methods of interagency interest could be
evaluated and to coordinate cross-agency issues on development,
validation, acceptance, and national and international harmonization of
toxicological test methods. The ICCVAM Authorization Act of 2000 (42
U.S.C. 285l-3, Public Law 106-545) established ICCVAM as a permanent
interagency committee of NIEHS under NICEATM. The law was enacted ``To
establish, wherever feasible, guidelines, recommendations, and
regulations that promote the regulatory acceptance of new or revised
scientifically valid toxicological tests that protect human and animal
health and the environment while reducing, refining, or replacing
animal tests and ensuring human safety and product effectiveness.''
Over the last 10 years, ICCVAM, with scientific support from
NICEATM, has evaluated over 185 test methods with the potential to
reduce, refine or replace the use of animals in regulatory safety
testing. ICCVAM has developed and transmitted recommendations to
Federal agencies for alternative methods for the four most commonly
used toxicity tests. These science-based technical evaluations have
been used to support adoption of test methods as guidelines by the
Organisation for Economic Co-operation and Development and other
international organizations. NICEATM and ICCVAM have also worked with
Federal agencies and other stakeholders to link research and
development activities to the standardization and validation of
alternative test methods that may be used in regulatory testing. The
symposium on February 5, 2008, will recognize the 10-year anniversary
of ICCVAM and discuss future directions in toxicology testing and the
NICEATM-ICCVAM Five-Year Plan.
Preliminary Agenda
Welcome
ICCVAM and NICEATM: The First Ten Years
A Vision Towards the Future: The NICEATM-ICCVAM Five-Year Plan
The Evolution and Future of Toxicology: Where We've Come From
and Future Prospects
Toxicology Testing in the 21st Century: A Vision and a
Strategy--A Report of the National Research Council of the National
Academies
Future Directions in Test Method Development--Toxicology
Research, Development, Translation, and Validation: Insights and
Activities from selected ICCVAM Agencies: NIEHS/NTP, EPA, FDA
Panel Discussion--Toxicology Research, Development,
Translation, and Validation: The Way Forward for ICCVAM and Its
Stakeholders
Closing Remarks
Symposium Attendance and Registration
The symposium will be held on Tuesday, February 5, 2008, from 1-5
p.m., in the CPSC Hearing Room, located at CPSC Headquarters, Bethesda
Towers Bldg., 4330 East West Highway, Bethesda, MD. The symposium is
open to the public and there is no charge to attend; attendance is
limited only by the available space. Individuals who plan to attend are
encouraged to register in advance with NICEATM. Registration
information is available on the NICEATM-ICCVAM Web site at https://
iccvam.niehs.nih.gov/meetings/10thAnnivSymp/10thAnnivSymp.htm or by
contacting NICEATM (see FOR FURTHER INFORMATION CONTACT above). Persons
needing special assistance in order to attend, such as sign language
interpretation or other reasonable accommodation, should contact 919-
541-2475 voice, 919-541-4644 TTY (text telephone, through the Federal
TTY Relay System at 800-877-8339), or e-mail to
niehsoeeo@niehs.nih.gov. Requests should be made at least seven days in
advance of the event.
NICEATM-ICCVAM Five-Year Plan
NICEATM and ICCVAM, working in conjunction with Federal agency
program offices, have prepared the NICEATM-ICCVAM Five-Year Plan. The
plan describes how NICEATM and ICCVAM will facilitate the research,
development, translation (activities carried out to characterize if
there is evidence of relevance and applicability of a test method for a
specific testing purpose), validation, and regulatory acceptance of
alternative test methods. Acceptance of such methods will reduce,
refine, and replace the use of animals in testing, while maintaining
scientific quality and the protection of human health, animal health,
and the environment. Development of the plan took place over a 14-month
period during which there were multiple opportunities for comment on
the plan by ICCVAM stakeholders, the public, and the Scientific
Advisory Committee on Alternative Toxicological Methods (see Federal
Register notices: Vol. 71, No. 218, pp. 66172-73, November 13, 2006;
Vol. 72, No. 83, pp. 23831-32, May 1, 2007; and Vol. 72, No. 83, pp.
23832-33, May 1, 2007).
The plan addresses ICCVAM's vision to play a leading role in
fostering and promoting the development, validation, and regulatory
acceptance of scientifically sound alternative test methods both within
the Federal government and internationally. Implementing this plan
involves four key challenges. The first challenge is to identify
priority areas for the next five years and to conduct and facilitate
activities in those areas. The second challenge involves identifying
and promoting research initiatives that are expected to support the
future development of innovative alternative test methods. The third
challenge is to foster the acceptance and appropriate use of
alternative test methods through outreach and communication. The last
challenge is to develop partnerships and strengthen interactions with
ICCVAM stakeholders in order to facilitate meaningful progress.
The NICEATM-ICCVAM Five-Year Plan will be presented at the February
symposium and copies will be available. The NICEATM-ICCVAM Five-Year
Plan will also be available electronically after February 5 on the
NICEATM-ICCVAM Web site at https://iccvam.niehs.nih.gov/docs/
5yearplan.htm. Print copies may be obtained by contacting NICEATM (see
FOR FURTHER INFORMATION CONTACT above).
Background Information on ICCVAM and NICEATM
ICCVAM is an interagency committee composed of representatives from
15 Federal regulatory and research agencies that use or generate
toxicological information. ICCVAM conducts
[[Page 72729]]
technical evaluations of new, revised, and alternative methods with
regulatory applicability and promotes the scientific validation and
regulatory acceptance of toxicological test methods that more
accurately assess the safety and hazards of chemicals and products and
that refine, reduce, or replace animal use. The ICCVAM Authorization
Act of 2000 (available at https://iccvam.niehs.nih.gov/docs/about_docs/
PL106545.pdf) establishes ICCVAM as a permanent interagency committee
of the NIEHS under NICEATM. NICEATM administers ICCVAM and provides
scientific and operational support for ICCVAM-related activities.
NICEATM and ICCVAM work collaboratively to evaluate new and improved
test methods applicable to the needs of Federal agencies. Additional
information about ICCVAM and NICEATM is available on the NICEATM-ICCVAM
Web site at https://iccvam.niehs.nih.gov.
Dated: December 12, 2007.
Samuel H. Wilson,
Acting Director, National Institute of Environmental Health Sciences
and National Toxicology Program.
[FR Doc. E7-24799 Filed 12-20-07; 8:45 am]
BILLING CODE 4140-01-P
